HODGKIN'S LYMPHOMA
Clinical trials for HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing schedule for lymphoma drug shows promise in 66 patients
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) given every 6 weeks instead of every 3 weeks in 66 people whose Hodgkin's lymphoma or PMBCL had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disappear. The …
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Could a drug make stem cell transplants safer and more effective?
Disease control CompletedThis study tested a drug called palifermin in 34 adults with blood cancers who received stem cell transplants from unrelated donors. The goal was to see if palifermin could reduce severe chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Smart scans could spare hodgkin patients from extra chemo
Disease control CompletedThis study tested whether using an early PET scan after two rounds of chemo could help doctors choose the right amount of treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued s…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New drug may replace harsh chemo before transplant for hodgkin lymphoma patients
Disease control CompletedThis study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant for people with Hodgkin lymphoma that came back or didn't go away. 66 patients received two cycles of SGN-35, and PET scans were…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC